Deliang Guo PhD

Deliang Guo PhD
Asst ProfessorCollege of Medicineguo@416@osu.edu
Wiseman Hall 400 W 12th Avenue Columbus Ohio 43210
Phone:Fax: (614) 247-1877
  • Translational Therapeutics

General Research Interest

Oncogenic signaling transduction and cancer metabolism.

Research Description

Dr. Guo's lab's long term goal is to determine the key molecular targets in cancer metabolism and translate it to clinic. The lab's detailed research interests are to: 1) Investigate the molecular link between oncogenic signaling PI3K/Akt and Ras/MEK/ERK signaling with cancer metabolism. 2) Develop the strategy via targeting SREBP-1 to treat cancer. 3) Dissect cholesterol metabolism and its intersection with oncogenic signaling. 4) Delineate the relationship between autophagy and cancer metabolism, and determine the metabolomics profile in cancer. 5) Define lipid droplet role and its dynamic regulation in cancer and reveal its relationship with autophagy and cancer metabolism.

Current Publications

  • Guo Deliang, Geng F, Aggarwal R, Liu J, Yoo JY, Guo Q, Guo JY, Hurwitz B, Ru P, Cheng C, Joshi K, Ichiro Nakano, Kaur Balveen, Chakravarti ArnabInterplay of lipid droplets and autophagy regulates glioblastoma survival.Neuro Oncol 16 Suppl 3 iii9 7/1/2014
  • Guo D, Bell EH, Mischel P, Chakravarti ATargeting SREBP-1-driven lipid metabolism to treat cancer.Curr Pharm Des 20 2619-26 1/1/2014
  • Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Zhu S, Villa GR, Shackelford D, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PSThe mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.Clin Cancer Res 19 5722-32 10/15/2013
  • Cloughesy TF, Christofk HR, Black DL, Mischel PS, Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, Kurdistani SK, Eskin A, Nelson SF, Yong WH, Cavenee WKEGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.Cell Metab 17 1000-8 6/4/2013
  • Guo D, Bell EH, Chakravarti ALipid metabolism emerges as a promising target for malignant glioma therapy.CNS Oncol 2 289-99 5/1/2013
  • Ru P, Williams TM, Chakravarti A, Guo DTumor metabolism of malignant gliomas.Cancers (Basel) 5 1469-84 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu